Back to News
Market Impact: 0.05
IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026
Source: globenewswire.com
Healthcare & Biotech
IMUNON, Inc., a clinical-stage biotechnology company developing DNA-mediated immunotherapies, announced it will host a conference call at 11:00 a.m. on Nov. 2, 2026. The excerpt provides no additional event details or clinical or financial updates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- RA Capital Management sells $9.13M in Lenz Therapeutics shares
- Karyopharm stock rating cut to neutral by Rodman on bankruptcy
- Bright Minds shares fall as BTIG cuts price target on clinical hold
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Vertex Pharma meets Q3 estimates, raises revenue guidance